-
Product Insights
New![]()
Net Present Value Model: ADC Therapeutics SA’s Camidanlumab tesirine
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: ADC Therapeutics SA’s ADCT-602
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADC-2122 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.ADC-2122 in Solid Tumor Drug Details: ADC-2122 is under development for the treatment of advanced or...
-
Product Insights
Westmass ADC/ Winn Dev – Ludlow Mills Mixed-Use Complex – Massachusetts
Equip yourself with the essential tools needed to make informed and profitable decisions with our Westmass ADC/ Winn Dev - Ludlow Mills Mixed-Use Complex - Massachusetts report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
![]()
ADC Therapeutics SA – Company Profile
ADC Therapeutics SA (ADC Therapeutics) is a biotechnology company that develops antibody-drug conjugates (ADCs) to treat hematologic malignancies and solid tumors. It offers Zynlonta, a CD-19-directed antibody for treatment of e B-cell lymphoma in adult patients. The company is provides Loncastuximab Tesirine (Lonca)and Camidanlumab Tesirine (Cami). ADC Therapeutics develops ADCT-602 drug for B-cell acute lymphoblastic leukemia, ADCT-601 targeting AXL in solid tumors, ADCT-901 against ovarian, triple-negative breast cancer and advanced solid tumors and ADCT-701 drug targeting DLK-1 in neuroblastoma, hepatocellular...
Add to Basket -
Product Insights
CAT Telecom/ China Telecom/ China Unicom/ PLDT Inc/ Singapore Telecomm/ SoftBank Group/ TATACOMM/ Viettel – ADC Submarine Cable System – South West
Equip yourself with the essential tools needed to make informed and profitable decisions with our CAT Telecom/ China Telecom/ China Unicom/ PLDT Inc/ Singapore Telecomm/ SoftBank Group/ TATACOMM/ Viettel - ADC Submarine Cable System - South West report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Breast Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BAT-8006 in Breast Cancer Drug Details: BAT-8006 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BAT-8006 in Ovarian Cancer Drug Details: BAT-8006 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Cervical Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BAT-8006 in Cervical Cancer Drug Details: BAT-8006 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BAT-8006 in Endometrial Cancer Drug Details: BAT-8006 is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BAT-8006 in Non-Small Cell Lung Cancer Drug Details: BAT-8006 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BAT-8006 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BAT-8006 in Solid Tumor Drug Details: BAT-8006 is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Bladder Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Bladder Cancer Drug Details: DS-1062 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Transitional Cell Cancer (Urothelial Cell Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Transitional Cell Cancer (Urothelial Cell Cancer) Drug Details: DS-1062 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Metastatic Biliary Tract Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Metastatic Biliary Tract Cancer Drug Details: DS-1062 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Solid Tumor Drug Details: DS-1062 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Drug Details: DS-1062...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Endometrial Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Endometrial Cancer Drug Details: DS-1062 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: DS-1062 is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Datopotamab Deruxtecan in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Datopotamab Deruxtecan in Triple-Negative Breast Cancer (TNBC) Drug Details: DS-1062 is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.